~~<i id='9398162D0D'><strike id='9398162D0D'><tt id='9398162D0D'><pre id='9398162D0D'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：fashion 2025-10-02 02:36:05 Page View：71518

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How housing is health care on Long Island
Next article： Drug repurposing or repositioning? The language matters

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Novo: Oral version of Ozempic leads to 15% weight loss

LISELOTTESABROE/AFP/GettyImagesAnoralversionofsemaglutide,thedrugmarketedasOzempicandWegovy,ledtodra

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

WATCH: Why do bright lights make us see spots?

Staringatthesunoratbrightlightswillleavebehindaspottyimprintinyourfieldofvision.Here'swhy.MatthewOrr